# Moderna **Source:** https://geo.sig.ai/brands/moderna **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** mrna.com **Last Updated:** 2026-04-14 ## Summary mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma. ## Company Overview Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows. Moderna's scientific platform is based on the revolutionary insight that mRNA can be designed to instruct cells to produce virtually any protein—including viral antigens for vaccines, antibodies, or therapeutic proteins—enabling a programmable medicine approach. The mRNA technology validated through COVID vaccine development creates a platform applicable to infectious disease, oncology, rare diseases, and cardiovascular conditions. Key 2024 milestones include FDA approval of mRESVIA, an mRNA RSV vaccine for adults 60+—the first respiratory disease vaccine beyond COVID—and the personalized cancer vaccine (PCV) developed with Merck using tumor-specific neoantigens delivered via mRNA, which demonstrated 44% reduction in recurrence in a melanoma Phase 2 trial when combined with Keytruda. In 2025-2026, Moderna's pipeline execution will determine whether the company can establish a sustainable commercial franchise beyond COVID. Next-generation vaccines under development include a combined flu/COVID mRNA combination vaccine, an mRNA cytomegalovirus (CMV) vaccine, latent tuberculosis treatment, and a next-generation pandemic preparedness portfolio. The personalized cancer vaccine partnership with Merck—which exercised its option for shared development rights in 2023—could generate blockbuster revenues if Phase 3 trials confirm Phase 2 results across multiple tumor types. Moderna competes with BioNTech (BNTX, Pfizer's COVID partner), Pfizer, and traditional vaccine makers GSK and Sanofi as mRNA platforms expand beyond COVID into established vaccine markets. ## Frequently Asked Questions ### What is Moderna and what does the company do? Moderna is a biotechnology company that pioneered the development of medicines and vaccines based on messenger RNA (mRNA) technology. The company's name combines 'modified' and 'RNA,' reflecting its focus on using synthetic mRNA to instruct human cells to produce therapeutic proteins. Unlike traditional pharmaceuticals, Moderna's mRNA platform can theoretically be programmed to produce any protein, enabling rapid development of treatments across multiple disease areas. Moderna became globally known for developing one of the first COVID-19 vaccines authorized for emergency use. Today, the company has 45+ programs in development across infectious diseases, oncology, rare diseases, and autoimmune conditions, with two approved products: Spikevax (COVID-19 vaccine) and mRESVIA (RSV vaccine). ### When was Moderna founded and who started the company? Moderna was founded in 2010 by a group of visionary scientists and entrepreneurs: Derrick Rossi (stem cell biologist whose research on mRNA-induced cell transformation inspired the company), Robert Langer (MIT chemical engineering professor and drug delivery expert), Noubar Afeyan (venture capitalist and chairman of Flagship Pioneering), Timothy A. Springer (immunologist), and Kenneth R. Chien (stem cell researcher). The company emerged from Rossi's breakthrough research showing that mRNA could be used to reprogram cells, suggesting the potential for an entirely new class of medicines. Stéphane Bancel was appointed CEO in 2011 and has led the company ever since, guiding it from a laboratory startup to a global biopharmaceutical company. ### How does Moderna's mRNA technology work? Moderna's mRNA technology works by delivering synthetic messenger RNA into human cells, where it instructs the cells to produce specific therapeutic proteins or antigens. For vaccines, the mRNA encodes a viral protein (antigen) that triggers an immune response, teaching the immune system to recognize and fight the actual pathogen. For therapeutics, the mRNA can encode proteins that replace deficient or malfunctioning proteins in genetic diseases, or stimulate immune responses against cancer. The mRNA is packaged in lipid nanoparticles that protect it from degradation and enable delivery into cells. Once inside, cellular machinery reads the mRNA instructions and manufactures the encoded protein. The mRNA is temporary and degrades naturally after a few days, while the produced protein triggers the desired therapeutic effect. This platform approach allows Moderna to design new medicines rapidly by simply changing the mRNA sequence. ### What products does Moderna currently sell? As of 2024-2025, Moderna has two approved commercial products. Spikevax is Moderna's mRNA COVID-19 vaccine, first authorized in December 2020 and subsequently approved for various age groups and updated formulations targeting evolving variants. In 2024, Spikevax generated $3.1 billion in sales, representing the vast majority of Moderna's revenue. mRESVIA (mRNA-1345) is Moderna's respiratory syncytial virus (RSV) vaccine, approved by the FDA in May 2024 for adults 60 years and older, and later expanded to adults 18-59 at increased risk. This was Moderna's second approved product, demonstrating that the mRNA platform could succeed beyond COVID-19. The company is working toward additional product approvals including seasonal influenza vaccine, combination flu/COVID vaccine, and cancer therapies, with multiple programs in late-stage clinical trials. ### How did Moderna perform financially in 2024? In 2024, Moderna generated total revenues of $3.2 billion, representing a 52.9% decline from $6.8 billion in 2023, reflecting reduced demand for COVID-19 vaccines as the pandemic emergency phase ended. Spikevax sales were $3.1 billion for the full year. The company reported a loss of $9.28 per share, though this was narrower than the $12.33 per share loss in 2023. Moderna achieved a notable milestone in Q3 2024 by posting a surprise profit of $13 million ($0.03 per share), demonstrating that cost-cutting efforts were taking effect. Chief Financial Officer Jamey Mock highlighted that Moderna reduced costs by 27% in 2024 compared to 2023, with a goal of achieving $1.1 billion in savings by 2027. For 2025, Moderna expects revenues of $1.5-$2.5 billion, primarily from COVID-19 and RSV vaccines, as the company transitions from pandemic-era revenues to a more sustainable commercial model. ### What is in Moderna's pipeline beyond COVID-19 vaccines? Moderna entered 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Key programs include: mRNA-1010, a seasonal influenza vaccine that demonstrated 26.6% superior efficacy versus standard vaccines in Phase 3 trials, with regulatory filing anticipated; mRNA-1083, a combination flu/COVID vaccine in Phase 3, though approval timeline has been extended to 2026 pending additional efficacy data; mRNA-1647, a CMV (cytomegalovirus) vaccine in pivotal Phase 3 evaluating efficacy in preventing infection in women of childbearing age; mRNA-1283, a next-generation refrigerator-stable COVID-19 vaccine with FDA decision expected May 31, 2025; mRNA-1403, a trivalent norovirus vaccine in two-season Phase 3 trial; mRNA-4157, an individualized cancer vaccine in Phase 3 for melanoma and lung cancer; and newly prioritized programs for Epstein-Barr virus (mRNA-1189), Varicella-Zoster virus (mRNA-1468), and an oncology checkpoint therapy (mRNA-4359). This diverse pipeline demonstrates Moderna's strategy to leverage its mRNA platform across multiple therapeutic areas. ### What is the company culture like at Moderna? Moderna's culture is built on a mission to deliver the greatest possible impact to people through mRNA medicines, with foundational values of quality, integrity, and respect. The company developed 'Moderna Mindsets,' a set of 12 cultural principles that guide how employees overcome challenges and work together. These mindsets emphasize tenacity, boldness, and collaboration. Moderna fosters a culture where employees feel a deep sense of responsibility for each other, patients, the environment, and local communities. With more than 4,350 people globally, the company focuses on creating an environment rooted in a strong sense of belonging. Notably, Moderna has achieved gender balance with 50% of employees and 41% of leadership identifying as female. According to Great Place to Work certification, 73% of Moderna employees say it is a great place to work, compared to 57% at typical U.S. companies. Employees highlight that 'the people and culture of collaboration at Moderna are second to none,' though some note the work is fast-paced and mentally demanding, requiring employees to set their own boundaries around work-life balance. Benefits include health insurance, retirement plans, paid time off, and opportunities for service projects. The culture reflects the urgency of Moderna's mission to develop transformative medicines while maintaining scientific rigor and ethical standards. ### How is Moderna positioned in the biotechnology industry? Moderna is positioned as a pioneer and leader in mRNA therapeutics, a rapidly growing segment of the biotechnology industry. The global mRNA therapeutics market was valued at $11.75 billion in 2023 and is projected to reach $31.30 billion by 2030, with a CAGR of 17.05%. Moderna holds approximately 28% market share based on projected 2024 platform sales, competing primarily with BioNTech and other emerging mRNA companies. The competitive landscape remains intense with key players including Moderna, BioNTech, Pfizer, CureVac, and others focusing on advancing mRNA platform technologies. Moderna differentiates itself through its broad pipeline spanning vaccines and therapeutics across multiple disease areas, significant investment in manufacturing infrastructure, strategic partnerships including collaboration with IBM on AI and quantum computing, and proven ability to execute at scale as demonstrated by COVID-19 vaccine deployment. Industry trends favor Moderna's strategy, including expansion beyond vaccines into oncology and rare diseases, personalized medicine approaches including cancer vaccines in clinical trials, and emphasis on efficient and scalable manufacturing processes. Government support remains strong, with the U.S. Department of Health and Human Services allocating $590 million to Moderna in January 2025 for mRNA technology capabilities and pandemic preparedness. ### What do patients say about Moderna's vaccines? Patient reviews of Moderna's COVID-19 vaccine show mixed experiences, with ratings varying across platforms. On Drugs.com, the vaccine has an average rating of 4.8 out of 10, with 34% of reviewers reporting positive experiences and 41% reporting negative experiences. On AskaPatient.com, 108 patient ratings average 3.9 out of 10. Positive testimonials highlight effective protection against COVID-19, with some patients reporting no side effects across multiple doses and no infection despite exposure. Many patients express gratitude for being vaccinated and protected. Negative reviews mention side effects including injection site reactions, fatigue, flu-like symptoms, headaches, and in some cases more severe reactions like extreme pain, tingling, brain fog, and lethargy. Some 2024 reviews noted specific adverse experiences including tingling and burning sensations in extremities and flu-like symptoms following vaccination. However, clinical data and post-marketing surveillance strongly support a positive benefit-risk profile favoring vaccination across all age groups. Real-world evidence published in 2024 demonstrates that Moderna COVID-19 vaccines are effective in preventing severe disease, hospitalization, and death from COVID-19, with safety profiles consistent with clinical trial data. ### What major challenges and opportunities does Moderna face? Moderna faces several challenges in 2024-2025: declining COVID-19 vaccine revenues as pandemic emergency ends, requiring transition to sustainable commercial model; intense competition in mRNA therapeutics from BioNTech, Pfizer, and emerging players; patent litigation including November 2024 lawsuit from GSK alleging infringement of mRNA technology patents; need to demonstrate clinical and commercial success of pipeline programs beyond COVID-19 to justify valuation; execution risk in advancing 45+ programs simultaneously with finite resources; and cost management pressure, requiring $1.1 billion in savings by 2027 while maintaining R&D investment. However, Moderna also has significant opportunities: validated mRNA platform with proven ability to develop and manufacture at scale; strong cash position and resources from COVID-19 vaccine sales to fund pipeline; multiple late-stage programs approaching potential approval, including influenza vaccine showing superior efficacy; growing market for mRNA therapeutics projected to reach $31.3 billion by 2030; continued government support including $590 million allocation in January 2025 for pandemic preparedness; and potential for personalized cancer vaccines and other breakthrough therapies that could transform treatment paradigms. Moderna's success will depend on efficiently converting its pipeline into approved products while managing costs and maintaining innovation. ### How can I invest in Moderna or explore career opportunities? Moderna stock trades on NASDAQ under ticker symbol MRNA and can be purchased through any brokerage account. The stock is widely followed by analysts and investors interested in biotechnology and mRNA therapeutics. Investors can access detailed information through Moderna's investor relations website at investors.modernatx.com, which provides financial reports, earnings calls, pipeline updates, and corporate presentations. The company does not currently pay dividends, as it is reinvesting resources in pipeline development and infrastructure. For career opportunities, Moderna offers positions across research and development, clinical operations, manufacturing, quality, regulatory affairs, commercial functions, and corporate support. The company emphasizes its mission-driven culture and opportunities to work on transformative medicines. Prospective employees can explore opportunities at modernatx.com/careers. Moderna values diversity and seeks individuals who embody tenacity, boldness, and collaboration. The company offers competitive compensation and benefits including health insurance, retirement plans, and professional development opportunities. With over 4,350 employees globally and expanding operations, Moderna provides opportunities for scientists, engineers, clinicians, business professionals, and others passionate about advancing mRNA medicine. ### What is Moderna's relationship with government agencies and pandemic preparedness? Moderna has significant relationships with government agencies focused on pandemic preparedness and public health. In 2023, the U.S. government allocated $1 billion to expand Moderna's mRNA research capabilities. In January 2025, the Department of Health and Human Services announced allocation of $590 million to Moderna for enhancing mRNA technology capabilities and accelerating development of mRNA-based pandemic influenza vaccines, demonstrating ongoing government investment in Moderna's platform for national security and public health preparedness. The company's COVID-19 vaccine development was supported by Operation Warp Speed, which provided funding and guaranteed purchase commitments that enabled rapid development and manufacturing scale-up. Moderna has supply agreements with numerous governments worldwide for COVID-19 vaccines and is positioned as a key partner in pandemic preparedness strategies. The company's manufacturing facilities, including the Montreal plant scheduled to supply vaccines beginning fall 2025, are designed to enable rapid response to emerging infectious disease threats. These government partnerships reflect recognition of mRNA technology's potential for rapid vaccine development against novel pathogens, a capability that could prove critical in future pandemic scenarios. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*